Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction

NCT07347197 is registered in ClinicalTrials.gov with Heartseed Inc. as lead sponsor.

NCT NCT07347197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07347197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction
Lead sponsor
Heartseed Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
January 31, 2030
Enrollment
14 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dilated cardiomyopathy (dcm), heart failure, ischemic heart disease, ischemic heart failure